Immunotherapy with ICIs may be a potential option for the treatment of advanced refractory TETs, considering the high frequency of PD-L1 expression particularly in type B3 thymoma and thymic carcinoma and the lack of recognized effective therapies other than platinum-based chemotherapy [39]. The gene discussed is CD274; the disease is thymic carcinoma.